Literature DB >> 7626321

Effects of bisphosphonates APD and HEBP on bone metabolism in vitro.

A Goziotis1, B Sukhu, M Torontali, M Dowhaniuk, H C Tenenbaum.   

Abstract

Although the effects of the bisphosphonates on resorption have been well documented, their effects on bone formation are not as clear. Therefore, this investigation was undertaken to elucidate the role played by bisphosphonates in the regulation of bone formation in vitro. To evaluate bisphosphonate-mediated regulation of bone formation in vitro, the effects of two drugs, ethane-1-hydroxy,1-diphosphate (Etidronate) (HEBP), and the second-generation bisphosphonate, disodium-1-hydroxy-1-aminopropylidine-1,1-diphosphate (Pamidronate) (APD), were assessed in the chick periosteal osteogenesis (CPO) model. In this study, drug-induced changes in alkaline phosphatase were assessed at the cellular level by means of quantitative fluorescence histochemistry. Cellular proliferation was quantified by means of autoradiography ([3H]thymidine). Mineralization and matrix production were measured morphometrically, whereas collagen synthesis and degradation were measured biochemically. The data suggest that in addition to their effects on bone resorption, the bisphosphonates have marked and direct effects on bone formation and other parameters of osteogenesis. HEBP may affect cellular proliferation (75-80% reduction, p < 0.05) in zones distant from bone; alkaline phosphatase positive cell numbers were increased in the osteoblastic layer of cells (twofold relative to control, p < 0.05) in 12-day cultures. HEBP, but not APD, prevented mineralization-induced suppression of matrix synthesis in early stages of culture. In 6-day cultures induced to mineralize with beta-glycerophosphate, (GP) cotreatment with HEBP induced a 70% increase in collagen synthesis. In addition, degradation of collagen in the CPO cultures was inhibited by HEBP (25%) and to a lesser extent by APD (8%). Although there were no differences in bone-osteoid areas measured in 12-day cultures treated with various regimens of bisphosphonate or GP, a clear increase in bone-osteoid area was detected in 6-day cultures treated with GP and HEBP as compared to GP only. This may suggest that initially, osteoblasts may be induced to synthesize increased volumes of bone matrix when mineralization is inhibited (e.g., with HEBP), but that over time the osteoblasts make the same amount of matrix. Taken together, these findings indicate that whereas the bisphosphonates do have well-documented effects on bone resorption, their effects on bone formation may also be important.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7626321     DOI: 10.1016/8756-3282(95)00044-e

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Authors:  N Morabito; A Gaudio; A Lasco; C Vergara; F Tallarida; G Crisafulli; A Trifiletti; M Cincotta; M A Pizzoleo; N Frisina
Journal:  Osteoporos Int       Date:  2003-05-15       Impact factor: 4.507

2.  Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

Authors:  Michaël Chaplet; Cédric Detry; Christophe Deroanne; Larry W Fisher; Vincent Castronovo; Akeila Bellahcéne
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

3.  The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts.

Authors:  A Ganguli; C Henderson; M H Grant; S T Meikle; A W Lloyd; I Goldie
Journal:  J Mater Sci Mater Med       Date:  2002-10       Impact factor: 3.896

4.  Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.

Authors:  P S Mackie; J L Fisher; H Zhou; P F Choong
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

5.  Added effect of 1% topical alendronate in intra-bony and inter-radicular defects as part of step II periodontal therapy: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Claudia Arena; Vito Carlo Alberto Caponio; Khrystyna Zhurakivska; Lucio Lo Russo; Lorenzo Lo Muzio; Giuseppe Troiano
Journal:  BMC Oral Health       Date:  2022-01-21       Impact factor: 2.757

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.